Profile data is unavailable for this security.
About the company
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
- Revenue in USD (TTM)7.47k
- Net income in USD-19.52m
- Incorporated1996
- Employees5.00
- LocationOragenics Inc1990 MAIN STREET, SUITE 750SARASOTA 34236United StatesUSA
- Phone+1 (813) 286-7900
- Fax+1 (813) 286-7904
- Websitehttps://www.oragenics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc | 5.63m | -6.08m | 3.86m | 13.00 | -- | 0.156 | -- | 0.6863 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 3.91m | 21.00 | -- | 3.28 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 3.93m | 22.00 | -- | 2.10 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Ainos Inc | 65.12k | -15.41m | 3.97m | 46.00 | -- | 0.1759 | -- | 60.91 | -3.17 | -3.17 | 0.0126 | 2.80 | 0.0019 | 0.7814 | 13.86 | 1,415.65 | -44.29 | -36.36 | -49.13 | -58.33 | -316.62 | 36.82 | -23,664.28 | -813.63 | 1.45 | -55.50 | 0.4016 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Trevena Inc | 443.00k | -37.03m | 4.01m | 23.00 | -- | -- | -- | 9.05 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Helix BioMedix, Inc. | 2.07m | -2.58m | 4.04m | 8.00 | -- | 2.59 | -- | 1.96 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Peak Bio Inc | 354.02k | -4.63m | 4.05m | -- | -- | -- | -- | 11.43 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.03m | 4.14m | 3.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | 0.9986 | 0.00 | -- | -- | 0.00 | -139.98 | -104.18 | -163.33 | -111.05 | -- | -- | -- | -- | -- | -563.88 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Oragenics Inc | 7.47k | -19.52m | 4.16m | 5.00 | -- | -- | -- | 556.41 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Creative Medical Technology Holdings Inc | 17.00k | -5.73m | 4.16m | 4.00 | -- | 0.5466 | -- | 244.80 | -4.07 | -4.07 | 0.012 | 5.69 | 0.0015 | 1.00 | -- | 4,250.00 | -51.83 | -110.00 | -53.71 | -- | 60.00 | 65.82 | -33,716.41 | -7,961.14 | 20.20 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -3.45m | 4.28m | 5.00 | -- | 0.2175 | -- | -- | -3.89 | -3.89 | 0.00 | 14.99 | 0.00 | -- | -- | 0.00 | -5.54 | -40.33 | -6.89 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Galera Therapeutics Inc | 0.00 | -29.11m | 4.30m | 7.00 | -- | -- | -- | -- | -0.5892 | -0.5892 | 0.00 | -2.54 | 0.00 | -- | -- | 0.00 | -90.03 | -83.69 | -119.01 | -97.54 | -- | -- | -- | -- | -- | -14.34 | 11.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Enveric Biosciences Inc | 0.00 | -10.59m | 4.38m | 7.00 | -- | 0.7155 | -- | -- | -3.67 | -3.67 | 0.00 | 0.6862 | 0.00 | -- | -- | 0.00 | -133.67 | -104.94 | -206.10 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 4.47m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Data as of Sep 21 2024. Currency figures normalised to Oragenics Inc's reporting currency: US Dollar USD
2.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Jun 2024 | 31.49k | 0.56% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 22.53k | 0.40% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 21.06k | 0.38% |
| Citadel Securities LLCas of 30 Jun 2024 | 16.51k | 0.30% |
| Virtu Americas LLCas of 30 Jun 2024 | 12.17k | 0.22% |
| Warberg Asset Management LLCas of 30 Jun 2024 | 10.00k | 0.18% |
| LionsBridge Wealth Management LLCas of 30 Jun 2024 | 10.00k | 0.18% |
| Tower Research Capital LLCas of 30 Jun 2024 | 5.05k | 0.09% |
| UBS Securities LLCas of 30 Jun 2024 | 990.00 | 0.02% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 150.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
